Daiichi Sankyo ups profit outlook, but weak spots mark nine-month figures
This article was originally published in Scrip
Daiichi Sankyo has pleased investors by revising its net profit forecast for the fiscal year ending 31 March on the back of cost cutting efforts and delayed R&D expenses, raising the expected figure by ¥15.0 billion to ¥70.0 billion ($853.2 million), a 67% increase over last year.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.